Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343
Kayo Yukawa-Takamatsu,Yifei Wang,Masaki Watanabe,Yuta Takamura,Michiko Fujihara,Mariko Nakamura-Nakayama,Shoya Yamada,Shota Kikuzawa,Makoto Makishima,Mayu Kawasaki,Sohei Ito,Shogo Nakano,Hiroki Kakuta
DOI: https://doi.org/10.1021/acs.jmedchem.0c01883
IF: 8.039
2020-12-30
Journal of Medicinal Chemistry
Abstract:Retinoid X receptor (RXR) modulators (rexinoids) are considered to have therapeutic potential for multiple diseases, such as Alzheimer's disease and Parkinson's disease. To overcome various disadvantages of prior screening methods, we previously developed an RXR binding assay using a fluorescent RXR ligand, CU-6PMN (<b>4</b>). However, this ligand binds not only at the ligand-binding domain (LBD) but also at the dimer–dimer interface of hRXRα. Here, we present a new fluorescent RXR antagonist 6-[<i>N</i>-ethyl-<i>N</i>-(5-isobutoxy-4-isopropyl-2-(11-oxo-2,3,6,7-tetrahydro-1<i>H</i>,5<i>H</i>,11<i>H</i>-pyrano[2,3-<i>f</i>]pyrido[3,2,1-<i>ij</i>]quinoline-10-carboxamido)phenyl)amino]nicotinic acid (NEt-C343, <b>7</b>), which emits strong fluorescence only when bound to the RXR-LBD. It allows us to perform a rapid, simple, and nonhazardous binding assay that does not require bound/free separation and uses a standard plate reader. The obtained <i>K</i>i values of known compounds were correlated with the <i>K</i>i values obtained using the standard [<sup>3</sup>H]9<i>cis</i>-retinoic acid assay. This assay should be useful for drug discovery as well as for research on endocrine disruptors, functional foods, and natural products.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01883?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01883</a>.Preparation of human RXRα-LBD, creation of human RXRα ligand-binding domain (LBD) coordinates, coordinates for compounds (input files), creating the grid box, creating input files and log files of docking simulations, calculation of the <i>Z</i>′ factor, statistical analysis, Schild analysis of <b>6</b> and <b>7</b> for hRXRα, transactivation of hRXR subtypes by <b>17</b> in the absence or presence of <b>7</b>, UV–vis absorbance and fluorescence spectra of fluorescein and <b>7</b>, relative fluorescence intensity data of 100 nM <b>7</b> in various solvents, chemical structure of CBTF-EE (<b>19</b>), binding assay protocol for rexinoids using <b>7</b> (λ<sub>Ex</sub> = 430 nm/λ<sub>Em</sub> = 535 nm), time course of <i>Z</i>′ factors during the competitive binding assay using 100 nM <b>7</b> with 500 nM hRXRα-LBD, chemical structures of rexinoids in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>B and natural ligands in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>C, fluorescence binding assay using <b>7</b> (λ<sub>Ex</sub> = 485 nm/λ<sub>Em</sub> = 535 nm), Schild plot slopes for <b>6</b> and <b>7</b> against <b>17</b>, calculated <i>K</i>i values obtained with <b>4</b>, <b>7</b>, and 9<i>cis</i>-RA, lists of PDB files, supporting movie legend, NMR spectra and HPLC charts (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_001.pdf">PDF</a>)Binding model of <b>7</b> (green stick model) in the antagonistic form with RXRα-LBD (PDB code: 3A9E) on AutoDock vina (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_002.mov">MOV</a>)RXR_LBD 3A9E.pdb (chain A from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_003.pdb">PDB</a>)Cpnd 5_mode1.pdb (mode 1 structure of NEt-SB (<b>5</b>) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_004.pdb">PDB</a>)Cpnd 6_mode1.pdb (mode 1 structure of NEt-BA (<b>6</b>) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_005.pdb">PDB</a>)Cpnd 6_mode2.pdb (mode 1 structure of NEt-BA (<b>6</b>) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_006.pdb">PDB</a>)Cpnd 7_mode1.pdb (mode 1 structure of NEt-C343 (<b>7</b>) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_007.pdb">PDB</a>)Cpnd 7_mode6.pdb (mode 6 structure of NEt-C343 (<b>7</b>) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_008.pdb">PDB</a>)LG_3A9E.pdb (binding structure of LG100754 (<b>18</b>) "754" from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_009.pdb">PDB</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_010.csv">CSV</a>)This article has not yet been cited by other publications.
chemistry, medicinal